BRPI0418756A - compositions and methods for inhibiting bone resorption - Google Patents

compositions and methods for inhibiting bone resorption

Info

Publication number
BRPI0418756A
BRPI0418756A BRPI0418756-3A BRPI0418756A BRPI0418756A BR PI0418756 A BRPI0418756 A BR PI0418756A BR PI0418756 A BRPI0418756 A BR PI0418756A BR PI0418756 A BRPI0418756 A BR PI0418756A
Authority
BR
Brazil
Prior art keywords
compositions
methods
vitamin
inhibiting
bone resorption
Prior art date
Application number
BRPI0418756-3A
Other languages
Portuguese (pt)
Inventor
Anastasia G Daifotis
Andrew Denker
Craig Ikeda
Bogdan Mataszewski
Sid Mazel
Arturo G Porras
Art Santora
Randal Alan Seburg
Limin Zhu
John Yates
John D Kirsch
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of BRPI0418756A publication Critical patent/BRPI0418756A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçõES E MéTODOS PARA INIBIR A REABSORçãO õSSEA". As composições e métodos são descritos para prevenir, inibir, reduzir e tratar condições e doenças associadas com reabsorção óssea anormal em mamíferos, incluindo por exemplo, osteoporose. Modalidades de composições da invenção compreendem uma quantidade farmaceuticamente eficaz de alendronato e vitamina D3 adequada para dosagem uma vez por semana. As composições e métodos da invenção fornecem nutrição de vitamina D durante o tratamento com bisfosfonato para facilitar a formação óssea normal e mineralização ao minimizar a ocorrência de ou potencial para as complicações associadas com insuficiência de vitamina D, tal como hipocalcaemia e osteomalacia. Da mesma forma descritos, são os métodos para fabricar composições da presente invenção, para medir a estabilidade e degradação dessas composições, e para medir os níveis de plasma sanguíneo de vitamina D."COMPOSITIONS AND METHODS FOR INHIBITING BONE RESORTION". Compositions and methods are described for preventing, inhibiting, reducing and treating conditions and diseases associated with abnormal bone resorption in mammals, including for example osteoporosis. Embodiments of compositions of the invention comprise a pharmaceutically effective amount of alendronate and vitamin D3 suitable for once weekly dosing. The compositions and methods of the invention provide vitamin D nutrition during bisphosphonate treatment to facilitate normal bone formation and mineralization by minimizing the occurrence or potential for complications associated with vitamin D insufficiency, such as hypocalcaemia and osteomalacia. Similarly described are the methods for making compositions of the present invention, for measuring the stability and degradation of such compositions, and for measuring vitamin D blood plasma levels.

BRPI0418756-3A 2004-05-19 2004-05-19 compositions and methods for inhibiting bone resorption BRPI0418756A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/015743 WO2005117906A1 (en) 2004-05-19 2004-05-19 Combination for inhibiting bone resorption comprising a bisphosponate (alendrona) and a vitamin d (cholecalciferol)

Publications (1)

Publication Number Publication Date
BRPI0418756A true BRPI0418756A (en) 2007-09-11

Family

ID=34958686

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418756-3A BRPI0418756A (en) 2004-05-19 2004-05-19 compositions and methods for inhibiting bone resorption

Country Status (4)

Country Link
EP (1) EP1758594A1 (en)
CN (1) CN1993134A (en)
BR (1) BRPI0418756A (en)
WO (1) WO2005117906A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745226B2 (en) 2005-04-06 2010-06-29 Quest Diagnostics Investments Incorporated Methods for detecting vitamin D metabolites
KR100822133B1 (en) * 2006-11-06 2008-04-15 한미약품 주식회사 Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate
US20100179110A1 (en) * 2006-12-20 2010-07-15 Mostafa Akbarieh Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
EP2127656A4 (en) * 2006-12-20 2010-03-03 Landsteiner Scient S A De C V Compositions of risedronate and vitamin d3
CN101444521B (en) * 2007-11-26 2012-07-04 信谊药厂 Pharmaceutical preparation containing alendronate sodium and cholecalciferol-cholesterol
US7972868B2 (en) 2007-11-28 2011-07-05 Quest Diagnostics Investments Incorporated Methods for detecting dihydroxyvitamin D metabolites by mass spectrometry
KR101102364B1 (en) * 2009-09-18 2012-01-03 한림제약(주) Pharmaceutical composition comprising bisphosphonate derivative and high amount of cholecalciferol
US7977117B2 (en) 2009-12-03 2011-07-12 Quest Diagnostics Investments Incorprated Vitamin D metabolite determination utilizing mass spectrometry following derivatization
JP5739903B2 (en) 2009-12-11 2015-06-24 クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド Mass spectrometry of steroidal compounds in complex samples
US20120025067A1 (en) 2009-12-11 2012-02-02 Quest Diagnostics Investments Incorporated Mass spectrometric determination of non-derivatized, non-metabolized vitamin d
CN102210697B (en) * 2010-04-02 2013-05-22 秦引林 Medicine composition for treating metabolic bone diseases
KR101230178B1 (en) * 2010-06-10 2013-02-06 주식회사 네비팜 A composition for treating or preventing osteoporosis and a method of preparing the same
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
CN113841052A (en) * 2018-10-18 2021-12-24 费森尤斯医疗保健控股公司 Techniques for modeling parathyroid function and calcimimetic drug activity
CN116082536B (en) * 2023-02-16 2024-04-26 广州汇元医药科技有限公司 Polymer with bone targeting function, preparation method and application thereof, nano-carrier and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0753523A1 (en) * 1995-07-10 1997-01-15 Gador S.A. Amino-substituted bisphosphonic acids
AR013994A1 (en) * 1998-10-30 2001-01-31 Gador Sa PROCEDURE AND PREPARATIONS THAT SELECTIVELY MODULATE THE FUNCTION OF THE OSTEOBLASTO FOR THE PREVENTION AND TREATMENT OF FRAGILIZING OSTEOPATHIES.
FR2814369B1 (en) * 2000-09-27 2004-05-21 Spmd DRUG VITAMIN D3 PREPARATION AND PROCESS FOR PRODUCING THE SAME
EP1416919A1 (en) * 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
US20050176685A1 (en) * 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
TWI344367B (en) * 2002-09-16 2011-07-01 Novartis Ag Use of zoledronic acid or a pharmaceutically acceptable salt or hydrate thereof in the preparation of a medicament for the treatment of osteoporosis post hip fracture

Also Published As

Publication number Publication date
CN1993134A (en) 2007-07-04
EP1758594A1 (en) 2007-03-07
WO2005117906A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
BRPI0418756A (en) compositions and methods for inhibiting bone resorption
WO2009137217A3 (en) Therapeutic replenishment and enrichment of ocular surface lubrication
BRPI0518315A2 (en) thiazole compounds that modulate hsp90 protein activity, associated inhibition, treatment and induction methods and pharmaceutical composition
WO2009039175A3 (en) Method for inhibiting bone resorption
BR112014004845A2 (en) at least one chemical entity; at least one compound; pharmaceutical composition; use of a therapeutically effective amount of at least one chemical entity; packaged pharmaceutical composition
PT721501E (en) PHARMACEUTICAL COMPOSITION WHICH UNDERSTAND PHOSPHATASE OR ITS DERIVATIVE
BR112015001419A2 (en) compound, pharmaceutical composition, and methods for inhibiting romk in a patient, causing diuresis, natriuresis, or both, and for treating one or more disorders.
RU2014127746A (en) COMPOSITION CONTAINING INHIBITING CRYSTALLIZATION OF SUBSTANCE
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
BR112015022538A2 (en) rituximab induction therapy followed by glatiramer acetate therapy
BR112012005837A8 (en) COMPOSITION OF DIGESTIVE ENZYMES IN MULTIPARTICLES, DOSAGE FORM, METHOD FOR TREATMENT OF PAIN ARISING FROM PANCREATITIS, METHOD FOR TREATMENT OF PAIN ARISING FROM PANCREATITIS AND PANCREATIC INSUFFICIENCY, METHOD FOR TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY AND METHOD FOR TREATMENT OF PAIN PANCREATIC
MX2010007242A (en) Pharmaceutical compositions comprising granules of purified microbial lipase and methods of preventing or treating digestive disorders.
BR112012003907A2 (en) pharmaceutical compositions for the prevention or treatment of osteoporosis, to be administered once a month
BRPI0514397A (en) 3-arylthioindole-2-carboxamide derivatives and analogues thereof as inhibitors of casein kinase epsilon
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
NO20083901L (en) Fixed-dose association of phytate and zinc
TW200719903A (en) Compositions for the treatment of neoplasms
SG10201406846XA (en) Bisphosphonate compounds for treating bone metabolism disorders
Naveau et al. Osteonecrosis of the jaw in patients taking bisphosphonates
BRPI0417123A (en) prolonged release torsemide formulation
NZ589618A (en) PAEDIATRIC COMPOSITIONS COMPRISING 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol FOR TREATING MULTIPLE SCLEROSIS
WO2010033980A3 (en) 4-azaindole bisphosphonates
MXPA04004807A (en) Compositions and methods for inhibiting bone resorption.
BR112018075067A2 (en) methods for the treatment of hypercalciuria and nephrolithiasis, therapeutic composition, nutritional composition, kit

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired